A Phase 1 Study Of The Safety And Immunogenicity Of Peptide-loaded Autologous Dendritic Cell Vaccination In Recurrent Respiratory Papillomatosis (RRP) Patients
Mayo Clinic
Summary
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Clinically confirmed diagnosis of recurrent respiratory papillomatosis. * Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required. * Human papilloma virus (HPV)6+ RRP in larynx * ECOG (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I). * The fo…
Interventions
- BiologicalAutologous HPV6 E6-and E7-derived peptide-loaded dendritic cell
Each patient will receive 5 doses autologous immunotherapy intradermally.
Location
- Mayo Clinic in ArizonaScottsdale, Arizona